Members I - L
I
IBB Beteiligungsgesellschaft mbH
IBB Beteiligungsgesellschaft mbH is providing equity financing to young technology-related and Berlin-based companies.
The IBB Beteiligungsgesellschaft mbH was founded in 1997 as a 100% subsidiary of the Investitionsbank Berlin with the mission to foster the development of regional businesses in selected areas and to strengthen the local labour market.
www.ibb-bet.de
Icon Genetics AG
ICON GENETICS is a provider of new plant engineering technologies which address precision, speed, yield, expression control and safety of transgene management in plants. We develop new generation production platforms and product prototypes for pharmaceutical, agricultural, animal health and chemical biotech markets.
www.icongenetics.com
Icon Clinical Research Ltd.
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I - IV clinical studies. In a higly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated "full service" solution.
www.iconclinical.com
IDEA AG
IDEA AG is a privately held biopharmaceutical company with headquarters in Munich, Germany. IDEA develops and commercializes non-invasive, targeted therapeutics, applied through the skin and/or nose. The Company"s leading Phase II and Phase III products are in the area of dermatology and pain treatment.
www.idea-ag.de
imaGenes GmbH
imaGenes is a premier provider of genome research services in Europe and was founded in 2007 as a spin-off from RZPD (German Resource Center for Genome Research). imaGenes manages one of the most comprehensive collections of clones of mammalian and vertebrate genes in the world offered via its clone search engine GenomeCube®, linked to international databases. The second major research services of imaGenes features microarray services on Affymetrix, Agilent, and NimbleGen platforms for a broad range of functional analyses. imaGenes is also offering next generation sequencing services on an Illumina Genome Analyzer System.
Researchers in academia and in the pharmaceutical industry are provided with highest quality resources and innovative technology with maximum flexibility and cost effectiveness. imaGenes is fully compliant with ISO 9001:2000 quality standards.
www.imagenes-bio.de
immatics biotechnologies GmbH
immatics is a biopharmaceutical company from Tuebingen/Germany. With presently 40 employees immatics develops peptide-based therapeutic vaccines for oncology. The most advanced product candidate, IMA901, addresses the unmet medical need in renal cell carcinoma. Based on very encouraging results from a recently completed phase 1 trial, IMA901 will soon be transferred to phase 2 clinical testing. A second product candidate, IMA910, will be ready for first-in-man clinical testing in patients with advanced-stage colorectal cancer in 2007.
www.immatics.com
IMTM GmbH
IMTM develops innovative products for the biopharmaceutical market, with particular emphasis in the area of inflammatory diseases. Additionally, IMTM offers preclinical and clinical services to the pharmaceutical industry. The dominant business field is the development of novel therapeutic strategies and drugs for the treatment of chronic inflammatory diseases.
www.imtm.de
Index Ventures
Indivumed GmbH
Indivumed supports the development of individual cancer therapies through close cooperation with Hamburg´s leading hospitals. The basis for research and development is a unique bio- and database, which provides ideal conditions for fast and close-to-patient development of tumor diagnostics and new drugs for cancer therapy.
www.indivumed.com
Ingenium Pharmaceuticals AG
Ingenium Pharmaceuticals is focused on the development of novel treatments for pain and inflammatory disease. Ingenium has successfully used its drug target discovery and genetics-based therapeutic research expertise for its internal drug development programs and for its partners.
www.ingenium-ag.com
INNOPHAR GmbH
The InnoPhaR GmbH is a clinical research organization with focus on the conduct of clinical studies in Eastern Europe. Besides first administration in man with young, healthy volunteers the main emphasis of its two own clinical units in the Ukraine and Moldova is the conduct of “Proof-of-Concept-Studies” using patients from various therapeutic areas.
www.ipr-ee.com
Institut Virion/Serion GmbH
Virion Serion has a very clear philosophy: since the company's foundation in 1978 we have been dedicated to supplying superior test kits for the diagnosis of infectious diseases - a hiqh target which requires continuous improvement and development of advanced diagnostic methods. At our Würzburg facilities, more than 100 highly qualified specialists combine their expertise to fulfill this task. With almost 30-year experience, Virion Serion stands for competence and reliability in in vitro diagnostics.
www.virion-serion.de
IntegraGen GmbH
Integragen GmbH, Bonn, was founded in June 2004. The company is a wholly owned subsidiary of Integragen SA, Evry, France.
Under a medical management the company is active in the field of complex genetic diseases. One of its main business focuses is molecular diagnostics of Diabetes mellitus.
www.integragen.de
Intendis GmbH
Intendis is an integrated pharmaceutical company based in Berlin, Germany. As part of Bayer HealthCare, Intendis is completely dedicated to Dermatology and focuses on the development and marketing of high quality, innovative topical therapies, targeted to treat skin disorders. The current product portfolio comprises treatments of eczema disorders including atopic dermatitis, as well as psoriasis, acne, rosacea, hemorrhoids and fungal skin infections (mycoses). Find out more at www.intendis.com.
www.intendis.com
Inter-Taxation AG
ipal GmbH
ipal GmbH – professional marketing of inventions and know-how
The ipal GmbH (innovations, patents, licenses) is supported by Berlin’s FU, HU, TU, FHTW and TFH universities and the Investment Bank Berlin (IBB). ipal GmbH evaluates the inventions and is their sole marketing agent. Based on cooperation treaties ipal works in the field of biotechnology for its strong Berlin partners Charité-Universitätsmedizin, Robert-Koch-Institut, Deutsches Herzzentrum, as well as for the Paul-Ehrlich-Institut in Langen and the International University Bremen. Ipal manages all services from the evaluation of patentable technologies to comprehensive patent protection and finally to the evaluation of market potential and commercialization of the invention.
www.ipal.de
Isenbruck, Bösl, Hörschler, Wichmann, Huhn - Patentanwälte
The patent attorney law firm Isenbruck | Bösl | Hörschler | Wichmann | Huhn consults clients in the protection of Intellectual Property, notably the prosecution, defence and enforcement of patents, utility models, trade marks and designs. The firm has offices in Mannheim, Munich, Heidelberg and Düsseldorf.
www.ib-patent.de
J
Jado Technologies GmbH
JADO´s mission is to develop novel small molecule drugs through our unrivalled insight into an emerging area of cell membrane chemistry centered on RAFTs (sub-compartments of cell membranes).
www.jado-tech.com
Jerini AG
The Biopharmaceutical company Jerini AG, Berlin, is specialized in the research, development and marketing of novel peptide-based drugs. The company applies its proprietary Peptides-to-Drugs (P2D) technology platform to develop medicaments for diseases, against which there are currently no or only limited treatments.
www.jerini.com
jobvector
jobvector is, for the German-speaking countries, the leading career platform for scientists on the Internet. Since 1999, our name is synonymous for high-quality placement service within the "life sciences" - in the fields of biotech, pharmaceutics, chemistry and medical research.
www.jobvector.com
Jones Day
JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH, a wholly owned subsidiary of Jerini AG, is a DIN EN ISO 9001:2000 certified biotechnology company based in Berlin and a leading supplier of innovative peptide-based services and products. JPT provides peptide arrays, peptide libraries and specialty peptides.
www.jpt.com
K
Kaye Scholer (Germany) LLP
KeyNeurotek Pharmaceuticals AG
K.H.S. Pharma Holdig GmbH
Kienbaum GmbH
Kienbaum ranks among Europe's leaders in management consulting. Our core competencies are Executive Search, Human Resource Management and Management Consulting. In Germany, we are the market leader in the search and selection of top management candidates and specialists (Executive Search) and personnel development, including compensation consulting (Human Resource Management).
www.kienbaum.de
Kinaxo Biotechnology GmbH
KINAXO supports pharmaceutical and biotechnology companies in the development and optimisation of small molecule drugs. Our comprehensive chemical-proteomics technology - known as KinaTorTM - identifies and characterizes the biological interactions of leads compounds with their cellular protein targets.
www.kinaxo.com
KPMG Deutsche Treuhand-Gesellschaft AG
KPMG International is an association of legally independent businesses with around 94,000 employees in 148 countries. It is one of the world"s leading auditing and advisory firms.
In Germany, KPMG is one of the leading players in this sector and has around 6,500 employees at over 20 locations. Our services are divided into the following functions: Audit, Tax and Advisory.
www.kpmg.com
L
Lederer & Keller
The patent law firm LEDERER & KELLER provides services in all aspects of intellectual property, in particular in patent and trademark law. The firm concentrates on protective rights in the fields of chemistry, pharmaceutical chemistry and biotechnology. The focus of work is drafting patent applications, patent prosecution, opposition proceedings, patent litigation, and general patent counseling.
www.lederer-keller.de
LipoNova GmbH
LipoNova specialises in the development, manufacturing, clinical testing and registration of innovative drugs in immunotherapy, with focus on tumor vaccination strategies. LipoNova has successfully conducted a phase-III trial on adjuvant treatment of renal cell carcinoma with autologous tumor cell lysate (aTL), full results published in "The Lancet", February 2004. LipoNova submitted its dossier for registration with the EMEA in December 2003. The company expects to receive European MA in the first quarter of 2006.
www.liponova.de
Lorenz Life Sciences Group
The LORENZ Life Sciences Group offers not only a document management system for managing scientific documents but at the same time offers a solution for creating both paper and electronic dossiers (eCTD) to be submitted to the Regulatory Authorities. What is specifically interesting for Biotech firms is that the software can also be implemented in such a way to manage a firm"s Due Diligence projects in-house.
www.lorenz-orga.de
LSC Life Science Consulting
LSC: Consulting and operative support in marketing & sales.
Scientifically trained staff with many years of experience in M&S and a multi-faceted network in the European Pharma and Biotech industry offers: Marketing strategies, Complete sales representation, Training of M&S personnel
www.life-science-consulting.ch
Lux Biosciences GmbH
Lux Biosciences is biotechnology company dedicated to the identification,
optimization, development and commercialization of products for the
treatment of ophthalmic diseases. The company"s business strategy is
characterized by:
A focus on compounds already marketed or with clinical
proof-of-concept in non-ophthalmic indications that Lux will develop as
unique, targeted therapies for corresponding ophthalmic diseases, with
potentially greater efficacy and safety than existing treatments.
A clinical and preclinical stage portfolio of projects including a
next-generation calcineurin inhibitor with potential in several ophthalmic
diseases and, as such, represents a pipeline of product opportunities. Lux
plans to begin pivotal clinical testing for the first indication by early
2007 and "if successful" this product will reach the market in 2009.
A proprietary product enabling bio-erodable polymer technology that
allows targeted delivery of Lux molecules to the eye.
www.luxbio.com